September 18, 2018
BEIJING, CHINA (September 18th, 2018) — The signing ceremony of the Repatha® Patient Assistance Program, initiated by the China Charity Foundation (CCF) and supported by Amgen, was successfully held today. Attending the launch ceremony were Wang Shufeng, Vice President of the China Charity Federation, Bian Zhiwei, Secretary-General of the China Charity Federation, Jiao Yahui, Deputy Director of the National Health Commission, Murdo Gordon, Executive Vice President of Amgen Global Commercial Operations, Zhang Wenjie, General Manager of Amgen China, Professor Li Dingguo, Director of the Shanghai Rare Disease Prevention Foundation and Chairman of the Rare Disease Branch of the Shanghai Medical Association and Ms. Wang Lvya, researcher at Beijing Anzhen Hospital of Peking Medical University and program medical expert volunteer. The program aims to supply patients suffering from homozygous familial hypercholesterolemia (HoFH) with free access to Repatha® (evolocumab) injections, an innovative, cholesterol-lowering drug. This measure will help to improve and prolong the quality of life for patients suffering from the disorder, while reducing the financial burden to the patients and their families.
HoFH is a rare disorder. It is estimated that one in 160,000 – 1,000,000 people is affected by HoFH1.HoFH is marked by elevated LDL-C level since birth, and subsequently an increased risk of developing overt atherosclerotic cardiovascular disease (ASCVD). If left untreated or poorly treated, most patients may suffer from angina or myocardial infarction during childhood or adolescence, which can lead to premature death, before the age of 20 to 302.
Prof. Li Dingguo, Director of the Shanghai Rare Disease Prevention Foundation and Chairman of the Rare Disease Branch of the Shanghai Medical Association, remarked that, “HoFH patients are at high risk of cardiovascular disease (CVD). As existing therapies have limitations, most patients fail to effectively control their LDL-C levels and are at continued risk of cardiovascular incidents.”
Repatha® was approved by the National Medical Products Administration (NMPA, former CFDA) in July 2018. This is the only PCSK9 inhibitor made available in China for the treatment of adults and adolescents over 12 years old suffering from HoFH. Working to achieve the most patient-oriented approach while satisfying the unmet needs of patients, the China Charity Federation, with the support of Amgen, quickly established the Repatha® Patient Assistance Program following the drug’s approval, further reducing the medical and financial burden on patients.
CCF’s vice president Wang Shufeng, maintained his strong support for the Repatha® Patient Assistance Program, stating, “This program is established to further improve diagnosis and treatment of HoFH, which helps the patients especially those teenagers with better life quality and bright future. We are calling for a joint-effort from across the whole of society to implement the Healthy China 2030 Strategy. The official launch of the program also marked another achievement by the CCF as we seek to help those suffering from rare diseases.”
“We hope the Repatha® Patient Assistance Program can play an exemplary role for the whole society and to encourage more enterprises to join us by supporting public welfare and implementing corporate social responsibility.” said Jiao Yahui, Deputy Director of the National Health Commission, “Let’s pay attention to the rare disease patients and safeguard their health rights.”
“HoFH is an area of critical unmet medical need. Together with CCF and other partners, we’re are delighted to bring new hope to Chinese patients with this rare disease,” said Murdo Gordon, Executive Vice President of Global Commercial Operations at Amgen. “As a leading global biotechnology company, Amgen is committed to discovering and developing breakthrough treatments for patients suffering from serious illnesses. We will continue to collaborate with CCF to bring Repatha® to as many HoFH patients in need as possible.”
The Repatha® Patient Assistance Program provides free drug assistance to patients suffering from HoFH who meet the application criteria for two years. For more information, please visit the official website of the Repatha® Patient Assistance Program.
About China Charity Federation (CCF)
China Charity Federation (CCF) is a nationwide non-governmental charity organization. Established in 1994, CCF was legally registered as an independent entity with approval from the Chinese government.
Since its establishment, CCF has maintained its goals of extending charitable work in various fields and increasing public awareness of the great difficulties faced by many members of our society. It has given wholehearted loyalty to China’s charitable concerns. CCF’s many humanitarian projects have drawn extensive social attention and have won the trust and support from the government.
In the past decades, CCF has been actively involved in humanitarian activities that have brought nationwide attention. Our projects include the following areas, which have greatly influence on all aspects of our society: disaster relief, poverty relief, care of seniors and orphans, education assistance, medical assistance and helping the disabled. So far, through extensive fundraising activities, CCF has raised more than 60 billion Yuan, both in cash and in kind. Currently, charitable relief projects are being carried out in more areas than ever before.
For more information, visit www.chinacharityfederation.org.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. Since its founded in 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, reaching millions of patients around the world and developing a pipeline of medicines with enormous potential.
Amgen has established its affiliates in China from 2012. By now they have built their China Headquarters and Asia Research & Development Center in Shanghai. Amgen also has an office in Beijing, which is responsible for drug registration and clinical trials with the aim to deliver its innovative drugs to patients in China. For more information, visit www.amgen.cn.
- Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management.A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014 Aug 21;35(32):2146-57
- 家族性高胆固醇血症筛查与诊治中国专家共识(Consensus of Chinese experts on the screening, diagnosis and treatment of Familial